Rafael Paez

Rafael Paez

Auto-generated profile, based on publicly available information

Rafael Paez

Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Chest
Verified
Journal Article
Closed access
SLSee-Wei Low
See-Wei Low
RLRobert J. Lentz
Robert J. Lentz
HCHeidi Chen
Heidi Chen
JKJames Katsis
James Katsis
MAMatthew C. Aboudara
Matthew C. Aboudara
FMFabien Maldonado
Fabien Maldonado

25 May 2023 in Chest
Verified
Journal Article
Closed access
RPRafael Paez
Rafael Paez
MKMichael Nolan Kammer
Michael Nolan Kammer
NTNicole T. Tanner
Nicole T. Tanner
SSSamira Shojaee
Samira Shojaee
BHBrent E. Heideman
Brent E. Heideman
FMFabien Maldonado
Fabien Maldonado

1 September 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
RPRafael Paez
Rafael Paez
RLRobert J. Lentz
Robert J. Lentz
JDJennifer D. Duke
Jennifer D. Duke
JSJustin K. Siemann
Justin K. Siemann
CSCristina Salmon
Cristina Salmon
FMFabien Maldonado
Fabien Maldonado
Rationale: Robotic-assisted bronchoscopy has emerged as an alternative to electromagnetic navigational bronchoscopy for patients undergoing bronchoscopic biopsy of a peripheral pulmonary lesion. Although both platforms are routinely used in clinical practice, comparative effectiveness data are lacking. Objectives: We sought to compare the effectiveness of robotic-assisted and electromagnetic navigational bronchoscopy for the evaluation of peripheral pulmonary lesions. Methods: In an investigator-initiated, single-center, cluster-randomized noninferiority trial, we assigned patients undergoing diagnostic bronchoscopy for evaluation of a peripheral pulmonary lesion to either robotic-assisted or electromagnetic navigational bronchoscopy. The cluster randomization unit was the operating room in which patients were scheduled. The primary outcome was the diagnostic yield of the procedure, defined as the proportion of cases yielding lesional tissue. Secondary and safety outcomes included procedure duration and complications. Measurements and Main Results: Among the 411 patients included in the modified intention-to-treat analysis, lesional tissue was obtained in 158 of 203 (77.8%) patients in the robotic-assisted group and 157 of 208 (75.5%) patients in the electromagnetic group; the P value for noninferiority was 0.007. The median duration of bronchoscopy was 37 minutes in the robotic-assisted group and 32 minutes in the electromagnetic group (difference, 5 min; 95% confidence interval = 2.0–7.7). Pneumothorax occurred in 4 patients in the robotic-assisted group and 6 patients in the electromagnetic group. Conclusions: In patients undergoing bronchoscopy for the evaluation of a peripheral pulmonary lesion, the diagnostic yield of robotic-assisted bronchoscopy was not inferior to that of electromagnetic navigation bronchoscopy. Clinical trial registered with www.clinicaltrials.gov (NCT 05705544).

22 December 2023 in Chest
Verified
Journal Article
Closed access
KLKaele M. Leonard
Kaele M. Leonard
SLSee-Wei Low
See-Wei Low
CECristina Salmon Echanique
Cristina Salmon Echanique
BSBriana A. Swanner
Briana A. Swanner
JJJoyce Johnson
Joyce Johnson
RLRobert J. Lentz
Robert J. Lentz

19 January 2024 in Trials
Verified
Journal Article
Open access
PDF file
RPRafael Paez
Rafael Paez
RLRobert J. Lentz
Robert J. Lentz
CSCristina Salmon
Cristina Salmon
JSJustin K. Siemann
Justin K. Siemann
SLSee-Wei Low
See-Wei Low
FIfor the Vanderbilt Learning Healthcare System Platform Investigators
for the Vanderbilt Learning Healthcare System Platform Investigators
Background: Robotic-assisted bronchoscopy has recently emerged as an alternative to electromagnetic navigational bronchoscopy for the evaluation of peripheral pulmonary lesions. While robotic-assisted bronchoscopy is proposed to have several advantages, such as an easier learning curve, it is unclear if it has comparable diagnostic utility as electromagnetic navigational bronchoscopy. Methods: Robotic versus Electromagnetic bronchoscopy for pulmonary LesIon AssessmeNT (RELIANT) is an investigator-initiated, single-center, open label, noninferiority, cluster randomized controlled trial conducted in two operating rooms at Vanderbilt University Medical Center. Each operating room (OR) is assigned to either robotic-assisted or electromagnetic navigational bronchoscopy each morning, with each OR day considered one cluster. All patients undergoing diagnostic bronchoscopy for evaluation of a peripheral pulmonary lesion in one of the two operating rooms are eligible. Schedulers, patients, and proceduralists are blinded to daily group allocations until randomization is revealed for each operating room each morning. The primary endpoint is the diagnostic yield defined as the proportion of cases yielding lesional tissue. Secondary and safety endpoints include procedure duration and procedural complications. Enrolment began on March 6, 2023, and will continue until 202 clusters have been accrued, with expected enrolment of approximately 400 patients by the time of completion in March of 2024. Discussion: RELIANT is a pragmatic randomized controlled trial that will compare the diagnostic yield of the two most commonly used bronchoscopic approaches for sampling peripheral pulmonary lesions. This will be the first known cluster randomized pragmatic trial in the interventional pulmonology field and the first randomized controlled trial of robotic-assisted bronchoscopy. Trial registration: ClinicalTrials.gov registration (NCT05705544) on January 30, 2023.

16 March 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RPRafael Paez
Rafael Paez
CSChirayu Shah
Chirayu Shah
ACAngelina J. Cords
Angelina J. Cords
AMAnel Muterspaugh
Anel Muterspaugh
JHJohn E. Helton
John E. Helton
PMPierre P. Massion
Pierre P. Massion
Background: 18F-fluorodeoxyglucose (FDG) PET/CT is recommended for evaluation of intermediate-risk indeterminate pulmonary nodules (IPNs). While highly sensitive, the specificity of FDG remains suboptimal for differentiating malignant from benign nodules, particularly in areas where fungal lung diseases are prevalent. Thus, a cancer-specific imaging probe is greatly needed. In this study, we tested the hypothesis that a PET radiotracer (S)-4-(3-[18F]-fluoropropyl)-L-glutamic acid (FSPG) improves the diagnostic accuracy of IPNs compared to 18F-FDG PET/CT. Methods: This study was conducted at a major academic medical center and an affiliated VA medical center. Twenty-six patients with newly discovered IPNs 7-30mm diameter or newly diagnosed lung cancer completed serial PET/CT scans utilizing 18F-FDG and 18F-FSPG, without intervening treatment of the lesion. The scans were independently reviewed by two dual-trained diagnostic radiology and nuclear medicine physicians. Characteristics evaluated included quantitative SUVmax values of the pulmonary nodules and metastases. Results: A total of 17 out of 26 patients had cancer and 9 had benign lesions. 18F-FSPG was negative in 6 of 9 benign lesions compared to 7 of 9 with 18F-FDG. 18F-FSPG and 18F-FDG were positive in 14 of 17 and 12 of 17 malignant lesions, respectively. 18F-FSPG detected brain and intracardiac metastases missed by 18F-FDG PET in one case, while 18F-FDG detected a metastasis to the kidney missed by 18F-FSPG. Conclusion: In this pilot study, there was no significant difference in overall diagnostic accuracy between 18F-FSPG and 18F-FDG for the evaluation of IPNs and staging of lung cancer. Additional studies will be needed to determine the clinical utility of this tracer in the management of IPNs and lung cancer.